Investigational Drug Information for Verubecestat
✉ Email this page to a colleague
What is the drug development status for Verubecestat?
Verubecestat is an investigational drug.
There have been 3 clinical trials for Verubecestat.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 5th 2013.
The most common disease conditions in clinical trials are Alzheimer Disease, Cognitive Dysfunction, and Cognition Disorders. The leading clinical trial sponsors are Merck Sharp & Dohme Corp. and [disabled in preview].
Summary for Verubecestat
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 109 |
WIPO Patent Applications | 96 |
Japanese Patent Applications | 1 |
Clinical Trial Progress | Phase 1 (2013-11-05) |
Vendors | 0 |
Recent Clinical Trials for Verubecestat
Title | Sponsor | Phase |
---|---|---|
An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016) | Merck Sharp & Dohme Corp. | Phase 1 |
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) | Merck Sharp & Dohme Corp. | Phase 3 |
An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738) | Merck Sharp & Dohme Corp. | Phase 2/Phase 3 |
Clinical Trial Summary for Verubecestat
Top disease conditions for Verubecestat
Top clinical trial sponsors for Verubecestat
US Patents for Verubecestat
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |